Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

Melanie E. Royce, MD, PhD
Published: Tuesday, Jan 31, 2017



Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

The most exciting part in the future is patient selection, she adds. What researchers are currently discovering are molecular tests for these patients to ensure they are being administered optimal therapy, Royce explains. Once these patients are determined, it may be appropriate to use more than 1 assay if it is necessary. 


Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

The most exciting part in the future is patient selection, she adds. What researchers are currently discovering are molecular tests for these patients to ensure they are being administered optimal therapy, Royce explains. Once these patients are determined, it may be appropriate to use more than 1 assay if it is necessary. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x